Yiling Pharmaceutical

Corporate brand

Unclaimed Request correction

Yiling Pharmaceutical is a Chinese pharmaceutical company focused on innovative traditional Chinese medicine.

Last updated October 9, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (stock code 002603) is a Chinese pharmaceutical company founded on 16 June 1992. Headquartered in Shijiazhuang, Hebei Province, it is a national key high-tech enterprise that develops traditional Chinese medicines, chemical drugs, and biological drugs using modern high technology. The company's stated purpose is "inherit and innovate, benefit mankind," with the development goal of "science and technology, health, tomorrow." It follows an innovation-driven development strategy led by the market and driven by science and technology, using academic innovation in traditional Chinese medicine to drive the industrialization of TCM. Yiling is best known for systematically constructing the collateral-disease (luobing) theory system and creating a distinctive "theory–clinic–new drug–industry–teaching" five-in-one operating model. This has formed an industrial cluster spanning "from medicine to drugs to health." The company's "TCM collateral-disease diagnosis and treatment methods" are listed as national-level intangible cultural heritage, and the textbook "Collateral Disease Theory" is taught at more than 40 universities across China. Yiling has undertaken more than 60 national and provincial-level research projects, including National 973, National 863, National Natural Science Foundation, and National Key R&D Program projects. Its core products include Tongxinluo Capsule for coronary heart disease and cerebral infarction, Shensong Yangxin Capsule for arrhythmia, Qili Qiangxin Capsule for chronic heart failure, Lianhua Qingwen Capsule for colds and influenza, and Bazishen Bushen Capsule for kidney essence supplementation and anti-aging. The company has developed more than 10 patented new drugs and obtained over 800 patents, winning six national awards including the National Science and Technology Progress First Prize and Second Prize. It operates five production and R&D bases in Hebei and Beijing, and has established more than 60 raw material bases for Chinese medicinal materials nationwide. Its production workshops have passed international certifications from the United States, the European Union, Canada, New Zealand, and other countries and regions, and it has established a comprehensive quality control system meeting international standards. Lianhua Qingwen is marketed in more than 30 countries. Yiling Pharmaceutical is ranked among China's Top 10 Traditional Chinese Medicine Enterprises, China's Top 20 Listed Pharmaceutical Companies, China's Top 500 Listed Companies by Market Value, and China's Top 100 Brand Value Enterprises. It has been awarded the title of "National Advanced Grass-roots Party Organization" by the Central Committee of the Communist Party of China. The company is listed on the Shenzhen Stock Exchange under the ticker 002603.

History

Yiling was established in 1992 in Shijiazhuang, Hebei, under the leadership of Wu Yiling. The enterprise was formed around the development and commercialization of traditional Chinese medicine and sought to give traditional formulations a more standardized pharmaceutical form. Rather than operating only as a traditional pharmacy or herbal-products company, it developed manufacturing, research, clinical, and distribution capabilities intended to support proprietary medicines. During its expansion, Yiling built a portfolio covering respiratory, cardiovascular, cerebrovascular, neurological, digestive, and other therapeutic areas. The company became particularly associated with patented traditional Chinese medicines, a category in which formula ownership, manufacturing consistency, clinical research, and regulatory registration are important elements of competitive positioning. Its research activities have also been connected with the broader modernization of traditional Chinese medicine through laboratory studies, clinical evaluation, and collaboration with medical and academic institutions. Yiling's corporate development culminated in the listing of Shijiazhuang Yiling Pharmaceutical Co., Ltd. on the Shenzhen Stock Exchange in 2011 under code 002603. The public-company structure gave the business access to capital markets and increased disclosure obligations, while its brand portfolio continued to be marketed primarily in China. The company subsequently maintained a mixed portfolio of prescription and over-the-counter medicines, health products, and related research or medical activities. Lianhua Qingwen became the company's most recognizable product line. It was developed as a respiratory traditional Chinese medicine and became widely known in China for influenza-related and other upper-respiratory symptoms. Its profile rose sharply during the COVID-19 pandemic, when Chinese authorities and medical institutions discussed traditional Chinese medicine as part of the national response. Yiling and its products then received substantial international attention, with distribution, registration, and public-health discussion extending beyond China. The pandemic period also produced the brand's most significant reputational challenge. International regulators and researchers distinguished between a product's approval or listing for particular indications in China and authorization to make COVID-19 treatment or prevention claims elsewhere. Questions were raised about the strength of clinical evidence, marketing language, and the applicability of traditional-medicine studies to different patient populations and health systems. These issues generated regulatory warnings and continuing scientific debate, but they do not by themselves establish that Yiling was found guilty of a criminal offense or that every claim made about the product was unlawful. Today, Yiling remains an active Chinese pharmaceutical brand and the commercial identity most closely linked to Shijiazhuang Yiling Pharmaceutical Co., Ltd. Its principal strategic themes are the industrialization of traditional Chinese medicine, development of patented formulations, expansion of modern research and manufacturing, and distribution of branded medicines. Its public profile is strongest in China, while international recognition is concentrated around selected products, especially Lianhua Qingwen. The brand's future reputation depends on maintaining regulatory compliance, communicating product indications precisely, and producing evidence that meets the requirements of the markets in which its medicines are sold.

2022
Evidence and authorization debate
[4]Nature Medicine discussion of COVID-19 therapeutics and evidencenature.com
Regulators and researchers continue to distinguish Chinese domestic product status from foreign authorization and debate the evidence base for COVID-19-related claims.
2020
Lianhua Qingwen gains international attention
[3]World Health Organization, Traditional medicine and COVID-19 materialswho.int
The COVID-19 pandemic substantially increases global attention to Lianhua Qingwen and to Yiling's traditional-medicine pharmaceutical model.
2011
Public listing
[2]Shenzhen Stock Exchangeszse.cn
Shijiazhuang Yiling Pharmaceutical Co., Ltd. is listed on the Shenzhen Stock Exchange under code 002603.
1992
Yiling is established
[1]Yiling official websiteyiling.cn
Wu Yiling establishes the enterprise in Shijiazhuang, Hebei, with a focus on traditional Chinese medicine research and commercialization.

Products and positioning

A research-oriented Chinese traditional-medicine pharmaceutical brand combining traditional Chinese medicine formulations with modern pharmaceutical manufacturing, clinical research, and branded commercialization.

Respiratory traditional Chinese medicine
Lianhua Qingwen
A branded traditional Chinese medicine formulation associated with respiratory symptoms and influenza-related use in China. It became Yiling's most internationally visible product during the COVID-19 pandemic. Its indications, legal status, labeling, and evidence base differ across jurisdictions; international publicity should not be interpreted as universal authorization for COVID-19 treatment or prevention.
Cardiovascular and cerebrovascular traditional Chinese medicine
Tongxinluo
A major Yiling patented-medicine line positioned for cardiovascular and cerebrovascular applications. It is part of the company's long-standing strategy of combining traditional Chinese medicine theory with standardized manufacturing and modern clinical research.
Cardiovascular traditional Chinese medicine
Yiqi Fumai
A Yiling cardiovascular medicine line associated with qi-supporting and circulation-related traditional Chinese medicine concepts. It forms part of the company's cardiovascular portfolio and is marketed subject to the regulatory requirements of each market.

Controversies

2022
Singapore authorities warn against treating COVID-19 with Lianhua Qingwen
Singapore’s health authorities stated that Lianhua Qingwen was not approved to prevent or treat COVID-19 and cautioned the public against relying on it for that purpose. The statement reflected regulatory concerns over…
2022
United States FDA issues import alert involving Lianhua Qingwen
The U.S. Food and Drug Administration listed an import alert covering certain unapproved or improperly labeled products marketed for COVID-19-related purposes, including Lianhua Qingwen. The action concerned U.S. regula…
2022
Regulatory controversy over Lianhua Qingwen COVID-19 claims
International regulators and health authorities challenged or restricted COVID-19-related interpretations and marketing of Lianhua Qingwen. Singapore stated that the product was not approved to prevent or treat COVID-19…
2022
Efficacy of Lianhua Qingwen and promotion for preventive use questioned; company issues public response
In April 2022, Yiling Pharmaceutical faced questions over the development timeline, efficacy, and preventive use of Lianhua Qingwen, and the company issued a statement explaining its research and trial evidence. The entry distinguishes approved indications from public misunderstanding of preventive use.
Source 1 Source 2 Source 3
2022
Online claims of liver injury spark safety discussion; company denies them and explains research basis
In December 2022, online claims emerged that Lianhua Qingwen could cause liver injury, and Yiling Pharmaceutical denied them and provided research evidence. The entry preserves the controversy and the company's position without confirming the alleged causal link or asserting that all use is risk-free.
Source 1 Source 2
2021
Undisclosed relationship between Lianhua Qingwen study author and pharmaceutical executive sparks conflict-of-interest controversy
In 2021, Caixin reported that the corresponding author of a study on Lianhua Qingwen against COVID-19 was married to a pharmaceutical company director, and the paper did not declare the relevant conflict of interest, sparking controversy over the independence of the research. The challenge is not equivalent to a finding that the study data were falsified.
Source

2020
International expansion of Lianhua Qingwen visibilityStrategy
Background
The pandemic created strong demand and public interest in respiratory products and traditional Chinese medicine outside China.
Action taken
Yiling pursued international distribution, registration, and communication for Lianhua Qingwen, subject to local regulatory frameworks.
Aftermath
The product gained global recognition but also faced scrutiny over evidence, labeling, and the difference between Chinese domestic status and authorization in other countries.
Source
2011
Transition to a listed pharmaceutical companyOther
Background
Yiling had expanded beyond an early research-focused traditional-medicine enterprise into a diversified pharmaceutical manufacturer.
Action taken
Shijiazhuang Yiling Pharmaceutical Co., Ltd. completed a public listing on the Shenzhen Stock Exchange.
Aftermath
The listing increased the company's access to capital and public reporting responsibilities.
Source

Recent events

2022
Lianhua Qingwen controversy in the United States[5]U.S. Food and Drug Administration consumer health-fraud guidancefda.gov
Regulation · Other
U.S. public-health and regulatory commentary emphasized that Lianhua Qingwen was not authorized by the U.S. Food and Drug Administration to prevent, diagnose, treat, or cure COVID-19. The episode highlighted differences between domestic product status and authorization in foreign markets.
2022
Debate over evidence for traditional Chinese medicine during the pandemic[4]Nature Medicine discussion of COVID-19 therapeutics and evidencenature.com
Regulation · Other
Researchers and commentators debated the quality, interpretation, and generalizability of studies concerning traditional Chinese medicine products, including Lianhua Qingwen, in COVID-19 care. The debate concerned evidence standards rather than a single confirmed corporate finding.
2020
International scrutiny of Lianhua Qingwen COVID-19 claims[3]World Health Organization, Traditional medicine and COVID-19 materialswho.int
Regulation · Other
The COVID-19 pandemic brought exceptional international attention to Lianhua Qingwen. Discussion centered on its use for respiratory symptoms, the scope of Chinese regulatory recognition, and whether available clinical evidence supported claims concerning COVID-19 treatment or prevention in other jurisdictions.
2020
Lianhua Qingwen becomes widely associated with COVID-19 response in China[16]连花清瘟在中国抗疫中被广泛关联who.int
Product generation · Other
Demand and public attention for Yiling’s Lianhua Qingwen product increased sharply during the COVID-19 pandemic. The product was used in China in connection with respiratory symptoms, while regulators and medical authorities continued to distinguish symptomatic or adjunctive use from proof that it could prevent or cure COVID-19.

Sources22 sources

Cite this profile: Cite the canonical profile. /brand-wiki/yiling · Editorial policy · How profiles are compiled